Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BN102 in R/R CLL/SLL and B-NHL
NCT05365100Phase 2Withdrawn
- Sponsor
- BioNova Pharmaceuticals
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docirbrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell non-Hodgkin lymphoma, mantle cell lymphoma (MCL), sponsored by BioNova Pharmaceuticals. Planned start Jul 2022; status: withdrawn.
02
Drugs
docirbrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)B-cell non-Hodgkin lymphomamantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05365100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05365100.